# Credit Suisse First Boston

> Credit Suisse First Boston is a VC fund backing Internet and Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Zurich, Switzerland
- Total investments: 24
- Last investment: Feb 2007
- Lead investor: 8%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/credit-suisse-first-boston-inc
- Website: http://www.csfb.com

Credit Suisse First Boston is a VC fund in Zurich focused on Internet and Biotechnology. Credit Suisse First Boston (informally CSFB) was the investment banking division of Credit Suisse Group, prior to 2006. It was active in investment banking, capital markets and financial services.

## Contacts

5 contacts available for Credit Suisse First Boston. Shizune tracks 3 team members at Credit Suisse First Boston. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/credit-suisse-first-boston?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Internet | 7 | 29% |
| Biotechnology | 4 | 17% |
| Manufacturing | 4 | 17% |
| Health Care | 3 | 13% |
| Service Industry | 3 | 13% |

33 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 9 | 38% |
| Series B | 4 | 17% |
| Series C | 4 | 17% |
| Private Equity | 2 | 8% |
| Series E | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 67% |
| United Kingdom | 2 | 8% |
| Canada | 1 | 4% |
| Bermuda | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Bottega | Director | 0 | https://shizune.co/investors/profile/john-bottega |
| Lawrence M. Schloss | Global Head and Chairman | 0 | https://shizune.co/investors/profile/lawrence-m-schloss |
| Marc Granetz | M&A Chief | 0 | https://shizune.co/investors/profile/marc-granetz |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PTC Therapeutics | PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $10M | Series F | Feb 05, 2007 |  |
| CELLFOR | CellFor is the world's leading independent supplier of high technology seedlings to the global forest industry. Using plant biotechnology, which is the use of biological processes to manufacture products, CellFor identifies and produces genetically superior conifer seedlings without genetic modification. | $4.6M |  | Oct 22, 2006 |  |
| Sunesis Pharmaceuticals | Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment toinnovation. | $14M | Series C | Sep 16, 2004 |  |
| PTC Therapeutics | PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $15M | Series E | Jun 23, 2004 |  |
| PTC Therapeutics | PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. Thecompany also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey. | $35M | Series E | Jan 07, 2004 |  |
| Aspen Insurance Holdings Limited | Aspen Insurance Holdings Limited is a company in the industry, with assets of $10.2 billion at the year ended December 31, 2013 and over 900 employees in eight countries. Founded in 2002, Aspen has been listed on the New York Stock Exchange since 2003 (NYSE:AHL). | $586.6M | Private Equity | Jun 01, 2002 |  |
| Oblix | As of March 28, 2005, Oblix, Inc. was acquired by Oracle Corp. The company develops identity-based security solutions for e-business networks. It offers Oblix NetPoint, a Web access management solution that provides an identity infrastructure for e-business environment. The company offers identity and Web services management, as well as accesscontrol and single sign-on to the enterprise and partner applications. Oblix, Inc. was founded in 1996 and is based in Cupertino, California. | $40M |  | Jan 02, 2002 |  |
| Sabeus Photonics | Sabeus Photonics optical devices and expand manufacturing facilities. Sabeus supplies optical communications components. | $16M | Series C | Dec 11, 2001 |  |
| iolon, inc. | iolon, Inc., is a privately held optical networking components company. The company provides high performance tunable devices for advanced fiber optic networks. iolon s initial product is a high-powered, external cavity, tunable laser source ideal for high bit rate, long haul applications. Future product lines include tunable filters, opticalswitches, polarization controllers, spectral monitors and universal transponders. iolon s platform technology enables advanced automation for high volume manufacturing based on patented micro-optics, MEMS and advanced servo control technologies. | $53M | Series B | Mar 01, 2001 |  |
| TrueSAN Networks | Founded in 1999, the company delivers enterprise storage networking systems, software and services for building scalable, intelligent, and universally accessible storage infrastructures. TrueSAN's next-generation storage solutions are designed to meet the unrelenting and unpredictable demand to store endless amounts of data. TrueSAN'stechnology provides unparalleled scalability, versatility, ease of use, as well as lower cost. | $30M | Series B | Jan 17, 2001 |  |

10 of 24 investments shown.

## Co-investors
- [Wheatley Partners](https://shizune.co/investors/profile/wheatley-partners) — VC Fund, 4 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 3 deals together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 3 deals together
- [Goldman Sachs](https://shizune.co/investors/profile/goldman-sachs) — VC Fund, 3 deals together
- [Merrill Lynch](https://shizune.co/investors/profile/merrill-lynch) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Credit Suisse First Boston invest in?

Credit Suisse First Boston invests primarily in Internet, Biotechnology and Manufacturing startups, most often at Funding Round and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Credit Suisse First Boston?

Public channels for Credit Suisse First Boston include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Credit Suisse First Boston?

The team at Credit Suisse First Boston includes John Bottega (Director), Lawrence M. Schloss (Global Head and Chairman) and Marc Granetz (M&A Chief). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co